Stock Evaluator: Atrium Therapeutics, Inc. (RNA)

Atrium Therapeutics, Inc. RNA

$6.98 0.34 5.12%
November 19, 2026 4:00:00 PM EST November 10, 2021 Volume: 225,886
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California. Atrium Therapeutics, Inc. was formerly a subsidiary of Avidity Biosciences, Inc.

Commentary & Analysis


Financial Summary

Share Statistics RNA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $150.6 $212.8 27%
Shares Out (Mil) 17.0 55.2 28%
Institutional Ownership 95.8% 93.3% 68%
Float (Mil) 19.5 40.8 28%
Beta na 1.03 na
Avg Daily Volume (000s) 211 559 45%
Price Change
(52-week)
na 40.3% na
Growth RNA Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) na (10.5%) na
EPS (5yr) na 15.4% na
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) na (15.7%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 1 1 2
Current EPS ($1.270) ($3.170) ($5.780)
Month Ago EPS ($1.370) ($3.610) ($6.390)
# Rev Up 1 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($1.720) ($4.550) ($8.060)
Year/Year Chg 408.0% (0.7%) 67.0%
Financials RNA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $39 $40 18%
Net Income (TTM) (Mil) ($70) ($44) 13%
EPS (TTM) ($4.282) ($1.400) 8%
Operating Cash Flow (TTM) (Mil) ($80) ($34) 7%
Net Cash Flow (TTM) (Mil) $45 $-0 69%
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) ($69) $142 1%
Valuation RNA Industry
Median
Percentile
(All Stocks)
P/B 0.56 1.97 14%
P/E na 16.8 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.8 na
Ratios RNA Industry
Median
Percentile
(All Stocks)
Gross Margin (54.8%) 67.6% 2%
Net Margin (180.9%) (50.8%) 5%
ROA (51.7%) (47.4%) 11%
ROE (95.0%) (51.4%) 9%
Liabilities to Assets 22.3% 29.6% 15%
F-Score 3 3 na

Atrium Therapeutics, Inc. did not pass any screens on 11/19/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors